gert de schoenmakere · curriculum vitae sylvie rottey 1 sylvie rottey molenstraat 45 9890 gavere...

Curriculum Vitae Sylvie Rottey 1

Sylvie Rottey

Molenstraat 45

9890 Gavere

Belgium

Work : Ghent University Hospital

Drug Research Unit Ghent | Department of Medical Oncology

Entrance 52 – Route 5210 | Entrance 50 – Route 535

Corneel Heymanslaan 10

9000 Ghent

Belgium

Tel: +32 9 332 28 11 | Fax: +32 9 332 62 85

E-mail : [email protected]

Civil status : married, De Schoenmakere Gert,

Nephrologist, AZ Delta Roeselare-Menen-Torhout

Children: Britt (06/06/2001) and Dries (09/09/2003)

Nationality : Belgium

Date of birth : 29/07/1972

Place of birth : Gent, Belgium

TRAINING

1983 - 1990 : Latin-Sciences

Institute Maria Middelares -Aalter

Great distinction

09/07/1993 : Candidate in Medical Sciences

University of Gent, Belgium

1st year : distinction

2nd year : distinction

3rd year : distinction

01/07/1997 : Medical Doctor

University Gent, Belgium

1st year : distinction

2nd year : great distinction

3rd year : the greatest distinction

4th year : great distinction

1997 – 1998 : Trainee in internal medicine – 1st year

Heilig Hartziekenhuis – Roeselare

3 months : geriatrics

4 months : endocrinology

3 months : cardiology

2 months : medical oncology

Curriculum Vitae

mailto:[email protected]


1998 – 1999 : Trainee in internal medicine – 2nd year

Heilig Hartziekenhuis - Roeselare

3 months : nephrology

3 months : gastro-enterology

5 months : pneumology

1 month : medical oncology

1999 – 2000 : Trainee in internal medicine – 3rd year (subdiscipline medical oncology)

University Hospital Gent

6 months : Medical Oncology – Prof. S. Van Belle

6 months : Hematology – Prof. W. Van Hove

2000 - 2001 : Trainee in internal medicine – 4th year (subdiscipline medical oncology)


12 months : Medical Oncology – Prof. S. Van Belle

2001 - 2002 : Trainee in internal medicine – 5th year (subdiscipline medical oncology)

Université Descartes Paris V

Hôpital Pitié-Salpétrière, Paris

12 months : medical oncology – Prof. D. Khayat

Institut Gustave Roussy, Paris

12 months : basic research fellow – medical genetics – Dr. J. Benard

2002-2003 : Trainee in medical oncology


Prof. S.Van Belle

October 2002 : Board Certificate of Internal Medicine

October 2003 : Application for the ‘Competence in Oncology in Internal Medicine’

October 2003 : Member of staff department Medical Oncology University Hospital Gent

30 March 2007 : PhD : Doctor in Medical Science 99mTc-HYNIC Annexin-V for monitoring response to chemotherapy:

methodology and feasibility studies.

Promotors : Prof. S. Van Belle and Prof. C. Van de Wiele

October 2008 : Associate Professor in Pharmacology

November 2008: Certificate of Clinical Pharmacology

October 2011 : Professor in Pharmacology

1 October 2015 : - Head of the Drug Research Unit Ghent (Phase I trials)

- Persisting staff member of the department of Medical Oncology (Head

and Neck cancers and Urogenital Cancers)

Currently working at the department of medical oncology as member of staff, responsible for

Head and Neck cancers and Urogenital Cancers.

Coordinator of the Oncology Phase I Unit of the hospital (from 2009 on).

Currently teaching different courses as professor in Pharmacology.


PRIZES

1997 : Prize for the best oral presentation during the BVN meeting

(Belgian Society of Nephrology), Brussels, Belgium

1997 : Scientific symposium of the Belgian Society for Internal

medicine, oral presentation : “Progression of renal failure in

patients with compromised renal function is not always

present: evaluation of underlying disease.”

Prize for the best oral presentation

1998 : VENEB, Belgium : Multipele adenopathies in an enlarged

small bowel meso in disseminated Giardia Lamblia

parasitosis.

Prize for the best oral presentation

2003 : Organotypic culture of primary breast cancer tissue :

feasibility of the multicellular spheroid model.

Prize for oral presentation – BSMO


PUBLICATIONS

Publications in international journals

1. Rottey S, Vanholder R, De Schoenmakere G, Lameire N. Progression of

renal failure in patients with compromised renal function is not always

present: evaluation of underlying disease. Clin Nephrol. 2000;54(1):1-10.

2. De Schoenmakere G, Vanholder R, Rottey S, Duym P, Lameire N.

Relationship between gastric emptying and clinical and biochemical

factors in chronic haemodialysis patients. Nephrol Dial Transplant.

2001;16(9):1850-5.

3. Van de Wiele C, Rottey S, Goethals I, Buscombe J, Van Belle S, De Vos F,

Dierckx RA. 99mTc sestamibi and 99mTc tetrofosmin scintigraphy for

predicting resistance to chemotherapy: a critical review of clinical data.

Nucl Med Commun. 2003;24(9):945-50.

4. Vermeersch H, Ham H, Rottey S, Lahorte C, Corsetti F, Dierckx R, Steinmetz

N, Van de Wiele C. Intraobserver, interobserver, and day-to-day

reproducibility of quantitative 99mTc-HYNIC annexin-V imaging in head

and neck carcinoma. Cancer Biother Radiopharm. 2004;19(2):205-10.

5. De Schoenmakere G, De Waele J, Terryn W, Deweweire M, Verstraete A,

Hoste E, Rottey S, Lameire N, Colardyn F. Phenytoin intoxication in critically

ill patients. Am J Kidney Dis. 2005;45(1):189-92.

6. Hennin C, Diederichsen E, Rottey L, Höfte M. Engineering disease

resistance in plants using the CF9-AVR9 two component system. Meded

Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2001;66(4):29-34.

7. Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP.

Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev

Oncol Hematol. 2006;59(1):51-64.

8. Rottey S, Slegers G, Van Belle S, Goethals I, Van de Wiele C. Sequential

99mTc-hydrazinonicotinamide-annexin V imaging for predicting response

to chemotherapy. J Nucl Med. 2006;47(11):1813-8.

9. Hoebeke PB, Rottey S, Van Heddeghem N, Villeirs G, Pauwels P,

Schrauwen W, Ceulemans P, Monstrey S. One-stage penectomy and

phalloplasty for epithelioid sarcoma of the penis in an adolescent. Eur Urol.

2007;51(5):1429-32.

10. Rottey S, Loose D, Vakaet L, Lahorte C, Vermeersch H, Van Belle S, Van de

Wiele C. 99mTc-HYNIC Annexin-V imaging of tumors and its relationship to

response to radiotherapy and/or chemotherapy. Q J Nucl Med Mol

Imaging. 2007;51(2):182-8.


11. Rottey S, Petrovic M, Bauters W, Mervillie K, Vanherreweghe E, Bonte K,

Van Belle S, Vermeersch H. Evaluation of metastatic lymph nodes in head

and neck cancer: a comparative study between palpation,

ultrasonography, ultrasound-guided fine needle aspiration cytology and

computed tomography. Acta Clin Belg. 2006;61(5):236-41.

12. Rottey S, Signore A, Van de Wiele C. Radiolabelled chemotherapeutics.

Q J Nucl Med Mol Imaging. 2007;51(2):139-51.

13. Hoebeke PB, Rottey S, Van Heddeghem N, Villeirs G, Pauwels P,

Schrauwen W, Ceulemans P, Monstrey S. One-stage penectomy and

phalloplasty for epithelioid sarcoma of the penis in an adolescent: part 2.

Eur Urol. 2007;51(6):1744-7.

14. Bambust I, Van Aelst F, Joosens E, Schallier D, Rezaei Kalantari H, Paulus Rs,

Renard V, Clausse M, Duck L, Luce S, Pierre P, Van Belle S, Rottey S. A

Belgian registry of interleukin-2 administration for treatment of metastatic

renal cell cancer and confrontation with literature data. Acta Clin Belg.

2007;62(4):223-9.

15. Ost P, Rottey S, Smeets P, Boterberg T, Stragier B, Goethals I. F-18

fluorodeoxyglucose PET/CT scanning in the diagnostic work-up of a

primary pericardial mesothelioma: a case report. J Thorac Imaging.

2008;23(1):35-8.

16. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J,

Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko

I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-

based chemotherapy plus cetuximab in head and neck cancer. N Engl J

Med. 2008;359(11):1116-27.

17. Rottey S, Van den Bossche B, Slegers G, Van Belle S, van de Wiele C.

Influence of chemotherapy on the biodistribution of

[99mTc]hydrazinonicotinamide annexin V in cancer patients. Q J Nucl

Med Mol Imaging. 2009;53(2):127-32.

18. Verbeke N, Verstraete K, Sys G, Forsyth R, Kluyskens D, Denys H,

Uyttendaele D, Rottey S. Osteosarcoma with extensive calcified pleural

metastases at diagnosis. Acta Clin Belg. 2008;63(5):325-8.

19. van Fraeyenhove F, Lamot C, Vogelaers D, Van Belle S, Cesmeli E, Rottey

S. A rare infectious complication after endoscopic ultrasound guided fine

needle aspiration in an oncological patient and review of the literature.

Acta Clin Belg. 2009;64(2):147-9.

20. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein

RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Efficacy and safety


of pazopanib in patients with metastatic renal cell carcinoma. J Clin

Oncol. 2010;28(3):475-80.

21. Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De

Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D,

Gross A, Vermorken JB. Quality of life of patients receiving platinum-based

chemotherapy plus cetuximab first line for recurrent and/or metastatic

squamous cell carcinoma of the head and neck. Ann Oncol.

2010;21(10):1967-73.

22. Verbaeys C, Hoebeke P, Van Belle S, Rottey S. Targeted therapy for

metastatic renal cell cancer. Acta Clin Belg. 2010;65(2):115-21.

23. Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, Rottey S, Kawecki A,

Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB.

Evaluation of EGFR gene copy number as a predictive biomarker for the

efficacy of cetuximab in combination with chemotherapy in the first-line

treatment of recurrent and/or metastatic squamous cell carcinoma of the

head and neck: EXTREME study. Ann Oncol. 2011;22(5):1078-87.

24. De Maeseneer DJ, Lambert B, Surmont V, Geboes K, Rottey SW. 18-

Fluorodeoxyglucose positron emission tomography as a tool for response

prediction in solid tumours. Acta Clin Belg. 2010;65(5):291-9.

25. Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys

H, Cocquyt V. Cardiac toxicity of trastuzumab: experience at the Ghent

Unversity Hospital, Belgium. Acta Clin Belg. 2010;65(5):300-4.

26. Rottey S, Madani I, Deron P, Van Belle S. Modern treatment for

nasopharyngeal carcinoma: current status and prospects. Curr Opin

Oncol. 2011;23(3):254-8.

27. Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H. PARP

inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

Acta Clin Belg. 2011;66(1):2-9.

28. Deron P, Mertens K, Goethals I, Rottey S, Duprez F, De Neve W, Vermeersch

H, Van de Wiele C. Metabolic tumour volume. Prognostic value in locally

advanced squamous cell carcinoma of the head and neck.

Nuklearmedizin. 2011;50(4):141-6.

29. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones

RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig

TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg

CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D,

Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.

Abiraterone and increased survival in metastatic prostate cancer. N Engl

J Med. 2011;364(21):1995-2005.


30. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin

J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O,

Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. An

international expanded-access programme of everolimus: addressing

safety and efficacy in patients with metastatic renal cell carcinoma who

progress after initial vascular endothelial growth factor receptor-tyrosine

kinase inhibitor therapy. Eur J Cancer. 2012;48(3):324-32.

31. Kruse V, Noens L, Lumen N, Hoebeke P, Van Belle S, Rottey S. High dose

chemotherapy and stem cell rescue for metastatic germ cell tumours:

long-term results from a single institution. Acta Clin Belg. 2011;66(4):254-9.

32. Combes M, Rottey S, De Backer T. Cardiovascular toxicity of cancer

treatment. Acta Clin Belg. 2011;66(4):260-6.

33. Lameire N, Kruse V, Rottey S. Nephrotoxicity of anticancer drugs--an

underestimated problem? Acta Clin Belg. 2011;66(5):337-45.

34. Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon

JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M,

Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O,

Machiels JP. Phase II study of everolimus in patients with locally advanced

or metastatic transitional cell carcinoma of the urothelial tract: clinical

activity, molecular response, and biomarkers. Ann Oncol.

2012;23(10):2663-70.

35. Vermassen T, Speeckaert MM, Lumen N, Rottey S, Delanghe JR.

Glycosylation of prostate specific antigen and its potential diagnostic

applications. Clin Chim Acta. 2012;413(19-20):1500-5.

36. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN,

North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr,

Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301

Investigators. Abiraterone acetate for treatment of metastatic castration-

resistant prostate cancer: final overall survival analysis of the COU-AA-301

randomised, double-blind, placebo-controlled phase 3 study. Lancet

Oncol. 2012;13(10):983-92.

37. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi

K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ,

Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen

WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano

CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302

Investigators. Abiraterone in metastatic prostate cancer without previous

chemotherapy. N Engl J Med. 2013;368(2):138-48.


38. Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels

JP. A phase Ib, open-label study to assess the safety of continuous oral

treatment with afatinib in combination with two chemotherapy regimens:

cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with

advanced solid tumors. Ann Oncol. 2013;24(5):1392-400.

39. Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S,

Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu

A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G,

Nardi M, Guthrie T, Boelle E, Magherini E. A randomized, double-blind,

placebo-controlled study to assess QTc interval prolongation of standard

dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc

Pharmacol. 2013;61(6):495-504.

40. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E,

Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S,

Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM

investigators. Cisplatin and fluorouracil with or without panitumumab in

patients with recurrent or metastatic squamous-cell carcinoma of the

head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Lancet Oncol. 2013;14(8):697-710.

41. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella

D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-

AA-301 Investigators. Effect of abiraterone acetate treatment on the

quality of life of patients with metastatic castration-resistant prostate

cancer after failure of docetaxel chemotherapy. Eur J Cancer.

2013;49(17):3648-57.

42. Vermassen T, Van Praet C, Vanderschaeghe D, Maenhout T, Lumen N,

Callewaert N, Hoebeke P, Van Belle S, Rottey S, Delanghe J. Capillary

electrophoresis of urinary prostate glycoproteins assists in the diagnosis of

prostate cancer. Electrophoresis. 2014;35(7):1017-24.

43. Van Praet C, Libbrecht L, D'Hondt F, Decaestecker K, Fonteyne V,

Verschuere S, Rottey S, Praet M, De Visschere P, Lumen N; Uro-Oncology

Group Ghent. Agreement of Gleason score on prostate biopsy and

radical prostatectomy specimen: is there improvement with increased

number of biopsy cylinders and the 2005 revised Gleason scoring? Clin

Genitourin Cancer. 2014;12(3):160-6.

44. Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S. Sunitinib

for metastatic renal cell cancer patients: observational study highlighting

the risk of important drug-drug interactions. J Clin Pharm Ther.

2014;39(3):259-65.


45. Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F, Van Den

Noortgate N, De Neve W, Rottey S, Geldhof K, Buyse V, Kargar-Samani K,

Ghekiere V, Debruyne PR. Serial comprehensive geriatric assessment in

elderly head and neck cancer patients undergoing curative radiotherapy

identifies evolution of multidimensional health problems and is indicative

of quality of life. Eur J Cancer Care (Engl). 2014;23(3):401-12.

46. Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G,

Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengeløv

L, Van Veldhuizen P, Agarwala SS, Sémiond D, Chadjaa M, Shen L, Wade

JL. An open-label study to investigate the cardiac safety profile of

cabazitaxel in patients with advanced solid tumors. Cancer Chemother

Pharmacol. 2014;73(6):1241-52.

47. Ruzsa A, Sen M, Evans M, Lee LW, Hideghety K, Rottey S, Klimak P,

Holeckova P, Fayette J, Csoszi T, Erfan J, Forssmann U, Goddemeier T,

Bexon A, Nutting C; NA EMD 1201081 Study Group. Phase 2, open-label,

1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in

combination with cetuximab in second-line cetuximab-naïve patients

with recurrent or metastatic squamous cell carcinoma of the head and

neck (R/M SCCHN). Invest New Drugs. 2014;32(6):1278-84.

48. Van Praet C, Decaestecker K, Fonteyne V, Ost P, De Visschere P,

Verschuere S, Rottey S, Lumen N. Contemporary minimally-invasive

extended pelvic lymph node dissection for prostate cancer before

curative radiotherapy: prospective standardized analysis of

complications. Int J Urol. 2014;21(11):1138-43.

49. Cornelis N, Vermassen T, Schallier D, Machiels JP, Gil T, Debruyne PR,

D'hondt R, Bols A, Schrijvers D, Mebis J, Lumen N, Rottey S. Prospective non-

interventional multicentre observational trial of first-line anti-cancer

treatment in patients with metastatic renal cell cancer in Belgium. Acta

Clin Belg. 2014;69(5):335-40.

50. Naert E, De Bleecker JL, Lumen N, Rottey S. Necrotizing myopathy as a

paraneoplastic syndrome associated with renal cell carcinoma. Acta Clin

Belg. 2015;70(1):61-4.

51. Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F, Maes A,

Goemaere S, Rottey S, Foubert I, Debruyne PR. Echium oil is not protective

against weight loss in head and neck cancer patients undergoing

curative radio(chemo)therapy: a randomised-controlled trial. BMC

Complement Altern Med. 2014;14:382.

52. Vermassen T, Van Praet C, Lumen N, Decaestecker K, Vanderschaeghe

D, Callewaert N, Villeirs G, Hoebeke P, Van Belle S, Rottey S, Delanghe J.


Urinary prostate protein glycosylation profiling as a diagnostic biomarker

for prostate cancer. Prostate. 2015 Feb 15;75(3):314-22.

53. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K,

Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS,

de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh

T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone

acetate plus prednisone versus placebo plus prednisone in

chemotherapy-naive men with metastatic castration-resistant prostate

cancer (COU-AA-302): final overall survival analysis of a randomised,

double-blind, placebo-controlled phase 3 study. Lancet Oncol.

2015;16(2):152-60.

54. De Maeseneer DJ, Van Praet C, Lumen N, Rottey S. Battling resistance

mechanisms in antihormonal prostate cancer treatment: Novel agents

and combinations. Urol Oncol. 2015 Jul;33(7):310-21.

55. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB,

Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de

Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ,

Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Afatinib versus

methotrexate as second-line treatment in patients with recurrent or

metastatic squamous-cell carcinoma of the head and neck progressing

on or after platinum-based therapy (LUX-Head & Neck 1): an open-label,

randomised phase 3 trial. Lancet Oncol. 2015;16(5):583-94.

56. Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S,

Lardon F, Smits E, Pauwels P. CD70: An emerging target in cancer

immunotherapy. Pharmacol Ther. 2015;155:1-10.

57. Machiels JP, Peeters M, Herremans C, Surmont V, Specenier P, De Smet M,

Pilz K, Strelkowa N, Liu D, Rottey S. A phase I study of volasertib combined

with afatinib, in advanced solid tumors. Cancer Chemother Pharmacol.

2015;76(4):843-51.

58. Bracarda S, Rottey S, Bahl A, Eichelberg C, Mellado B, Mangel L, Cattaneo

A, Panneerselvam A, Grünwald V. REACT expanded-access program in

patients with metastatic renal cell carcinoma: real-world data from a

European subanalysis. Future Oncol. 2015;11(21):2893-903.

59. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S,

Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK,

Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y,

Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA,

Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus

Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med.

2015;373(19):1803-13.


60. Vermassen T, Van Praet C, Poelaert F, Lumen N, Decaestecker K, Hoebeke

P, Van Belle S, Rottey S, Delanghe J. Diagnostic accuracy of urinary

prostate protein glycosylation profiling in prostatitis diagnosis. Biochem

Med (Zagreb). 2015;25(3):439-49.

61. Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F, Rottey S,

Lievens Y, Van Den Noortgate N, Geldhof K, Buyse V, Kargar-Samani K,

Ghekiere V, Debruyne PR. G-8 indicates overall and quality-adjusted

survival in older head and neck cancer patients treated with curative

radiochemotherapy. BMC Cancer. 2015;15:875.

62. Decoster L, Vande Broek I, Neyns B, Majois F, Baurain JF, Rottey S, Rorive A,

Anckaert E, De Mey J, De Brakeleer S, De Grève J. Biomarker Analysis in a

Phase II Study of Sunitinib in Patients with Advanced Melanoma.

Anticancer Res. 2015;35(12):6893-9.

63. Seront E, Rottey S, Filleul B, Glorieux P, Goeminne JC, Verschaeve V,

Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A,

Machiels JP. Phase II study of dual phosphoinositol-3-kinase (PI3K) and

mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with

locally advanced or metastatic transitional cell carcinoma. BJU Int.

2016;118(3):408-15.

64. Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F,

Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP,

Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse

M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne

JC, Lumen N. Abiraterone acetate post-docetaxel for metastatic

castration-resistant prostate cancer in the Belgian compassionate use

program. Urol Oncol. 2016;34(6):254.e7-254.e13.

65. Vermassen T, De Meulenaere A, Van de Walle M, Rottey S. Therapeutic

approaches in clear cell and non-clear cell renal cell carcinoma. Acta

Clin Belg. 2017 Feb;72(1):12-18.

66. De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P,

Duprez F, Ferdinande L, Rottey S. CD70 Expression and Its Correlation with

Clinicopathological Variables in Squamous Cell Carcinoma of the Head

and Neck. Pathobiology. 2016;83(6):327-33.

67. Van de Walle M, Demol J, Staelens L, Rottey S. Abscopal effect in

metastatic renal cell carcinoma. Acta Clin Belg. 2017;72(4):245-249.

68. De Scheerder MA, Rottey S, Mariman A, Praet M, Vogelaers D. How far to

investigate presumed psychosomatic symptoms: Lessons from a particular

case…. Acta Clin Belg. 2017;72(2):138-141.


69. Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C,

Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M,

Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R.

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib

in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label

Studies. Clin Ther. 2016;38(10):2286-2299.

70. Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-

Corbacho J, Mathijssen RHJ, Clot PF, Wack C, Shen L, de Jonge MJA. A

phase I pharmacokinetic and safety study of cabazitaxel in adult cancer

patients with normal and impaired renal function. Cancer Chemother

Pharmacol. 2016;78(6):1185-1197.

71. Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry

S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohee D, Dequanter D,

Louviaux I, Sautois B, Whenham N, Berchem G, Vanderschueren B,

Fontaine C, Schmitz S, Gillain A, Schoonjans J, Rottey S. Randomized Phase

II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent

and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Previously Treated With Platinum-Based Therapy. Oncologist.

2016;21(12):1416-e17.

72. De Meulenaere A, Vermassen T, Aspeslagh S, Vandecasteele K, Rottey S,

Ferdinande L. TILs in Head and Neck Cancer: Ready for Clinical

Implementation and Why (Not)? Head Neck Pathol. 2017;11(3):354-363.

73. Poelaert F, Kumps C, Lumen N, Verschuere S, Libbrecht L, Praet M, Rottey

S, Claeys T, Ost P, Decaestecker K, De Meerleer G, Van Praet C. Androgen

Receptor Gene Copy Number and Protein Expression in Treatment-Naïve

Prostate Cancer. Urol Int. 2017;99(2):222-228.

74. De Maeseneer DJ, Delafontaine B, Rottey S. Checkpoint inhibition: new

treatment options in urologic cancer. Acta Clin Belg. 2017;72(1):24-28.

75. Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, Ost P,

Devisschere P, Villeirs G, Fonteyne V, Decaestecker K. The independent

oncological role for cytoreductive nephrectomy in metastatic renal cell

carcinoma: Prognostic features in the era of targeted therapies. Urol

Oncol. 2017;35(4):152.e13-152.e22.

76. Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F,

Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP,

Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse

M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne

JC, Lumen N. Which Factors Predict Overall Survival in Patients With

Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone

Acetate Post-Docetaxel? Clin Genitourin Cancer. 2017;15(4):502-508.


77. Vermassen T, D'Herde K, Jacobus D, Van Praet C, Poelaert F, Lumen N,

Callewaert N, Decaestecker K, Villeirs G, Hoebeke P, Van Belle S, Rottey S,

Delanghe J. Release of urinary extracellular vesicles in prostate cancer is

associated with altered urinary N-glycosylation profile. J Clin Pathol.

2017;70(10):838-846.

78. Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou

V, Hauben E, Rolfo C, Rottey S, Pauwels P. CD70 and PD-L1 in anaplastic

thyroid cancer - promising targets for immunotherapy. Histopathology.

2017;71(3):357-365.

79. De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P,

Duprez F, Rottey S, Ferdinande L. Prognostic markers in oropharyngeal

squamous cell carcinoma: focus on CD70 and tumour infiltrating

lymphocytes. Pathology. 2017;49(4):397-404.

80. Vermassen T, Geboes K, De Man M, Laurent S, Decoene E, Lumen N,

Delanghe J, Rottey S. Neither creatinine- nor cystatin C-estimated

glomerular filtration rate is optimal in oncology patients treated with

targeted agents. Nephrol Dial Transplant. 2018;33(3):402-408.

81. De Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Van Dorpe J,

Ferdinande L, Rottey S. Turning the tide: Clinical utility of PD-L1 expression

in squamous cell carcinoma of the head and neck. Oral Oncol.

2017;70:34-42.

82. Duprez F, Berwouts D, De Neve W, Bonte K, Boterberg T, Deron P, Huvenne

W, Rottey S, Mareel M. Distant metastases in head and neck cancer. Head

Neck. 2017;39(9):1733-1743.

83. Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D,

Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P,

Reynders D, Van Gele M, Brochez L, Ost P. A phase I/II trial of fixed-dose

stereotactic body radiotherapy with sequential or concurrent

pembrolizumab in metastatic urothelial carcinoma: evaluation of safety

and clinical and immunologic response. J Transl Med. 2017;15(1):150.

84. Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir

M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D,

de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A. Phase I

Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced

Malignancies. Clin Cancer Res. 2017;23(21):6411-6420.

85. De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L,

Goetghebeur E, De Meerleer G, Lumen N, Fonteyne V, De Maeseneer D,

Ost P. Combined high dose radiation and pazopanib in metastatic renal


cell carcinoma: a phase I dose escalation trial. Radiat Oncol.

2017;12(1):157.

86. Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche

J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, Vangestel C,

Lardon F, Smits E, Pauwels P. Preclinical data on the combination of

cisplatin and anti-CD70 therapy in non-small cell lung cancer as an

excellent match in the era of combination therapy. Oncotarget.

2017;8(43):74058-74067.

87. De Meulenaere A, Vermassen T, Aspeslagh S, Deron P, Duprez F, Laukens

D, Van Dorpe J, Ferdinande L, Rottey S. Tumor PD-L1 status and CD8+

tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal

cancer. Oncotarget. 2017;8(46):80443-80452.

88. Cammaert T, Decaestecker K, Sundahl N, Rottey S, Devreese KMJ. A

patient with acquired factor X deficiency and metastatic transitional cell

carcinoma of the bladder: is there a link between metastasis and factor

deficiency in solid tumors? Ann Hematol. 2018;97(3):545-546.

89. Sundahl N, Rottey S, De Maeseneer D, Ost P. Pembrolizumab for the

treatment of bladder cancer. Expert Rev Anticancer Ther. 2018;18(2):107-

114.

90. Buelens S, Poelaert F, Dhondt B, Fonteyne V, De Visschere P, Ost P, Verbeke

S, Villeirs G, De Man K, Rottey S, Decaestecker K, Lumen N. Metastatic

burden in newly diagnosed hormone-naive metastatic prostate cancer:

Comparing definitions of CHAARTED and LATITUDE trial. Urol Oncol.

2018;36(4):158.e13-158.e20.

91. Schatteman J, Van Gestel D, Berwouts D, De Gersem W, De Kerf G, De

Neve W, De Ost B, Olteanu AML, Rottey S, Vercauteren T, Goethals I,

Duprez F. A feasibility study on adaptive 18F-FDG-PET-guided radiotherapy

for recurrent and second primary head and neck cancer in the previously

irradiated territory. Strahlenther Onkol. 2018;194(8):727-736.

92. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri

TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F,

Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud

A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen

AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers

HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab

versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med.

2018;378(14):1277-1290.

93. Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels

JH, Van Den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey


S, Braun N, Verma B, Gilham DE, Lehmann FF. Celyad's novel CAR T-cell

therapy for solid malignancies. Curr Res Transl Med. 2018;66(2):53-56.

94. De Meulenaere A, Vermassen T, Creytens D, Aspeslagh S, Deron P, Duprez

F, Rottey S, Van Dorpe JA, Ferdinande L. Importance of choice of materials

and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell

carcinoma. Histopathology. 2018;73(3):500-509.

95. Buelens S, De Bleser E, Dhondt B, Verla W, Decaestecker K, Ost P, Fonteyne

V, De Man K, Standaert C, Rottey S, Lumen N. Importance of metastatic

volume in prognostic models to predict survival in newly diagnosed

metastatic prostate cancer. World J Urol. 2018. [Epub ahead of print]

96. Fonteyne V, Rammant E, Ost P, Lievens Y, De Troyer B, Rottey S, De

Meerleer G, De Maeseneer D, De Ridder D, Decaestecker K. Evaluating

the Current Place of Radiotherapy as Treatment Option for Patients With

Muscle Invasive Bladder Cancer in Belgium. Clin Genitourin Cancer.

2018;16(6):e1159-e1169.

97. Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C,

Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer

J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E.

Pharmacokinetic Effects and Safety of Olaparib Administered with

Endocrine Therapy: A Phase I Study in Patients with Advanced Solid

Tumours. Adv Ther. 2018;35(11):1945-1964.

98. Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van

Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf

JB, Powles T, de Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette

L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive

Nephrectomy in Patients with Synchronous Metastatic Renal Cell

Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

JAMA Oncol. 2018. [Epub ahead of print]

99. Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere

P, Fonteyne V, De Maeseneer D, Reynders D, Goetghebeur E, Van Dorpe

J, Verbeke S, Annala M, Brochez L, Van der Eecken K, Wyatt AW, Rottey S,

Ost P. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus

Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial

Carcinoma. Eur Urol. 2019. [Epub ahead of print]

100. Machiels JP, Salazar R, Rottey S, Duran I, Dirix L, Geboes K, Wilkinson-Blanc

C, Pover G, Alvis S, Champion B, Fisher K, McElwaine-Johnn H, Beadle J,

Calvo E. A phase 1 dose escalation study of the oncolytic adenovirus

enadenotucirev, administered intravenously to patients with epithelial

solid tumors (EVOLVE). J Immunother Cancer. 2019;7(1):20.


101. Vermassen T, De Bruyne S, Himpe J, Lumen N, Callewaert N, Rottey S,

Delanghe J. N-Linked Glycosylation and Near-Infrared Spectroscopy in

the Diagnosis of Prostate Cancer. Int J Mol Sci. 2019;20(7).

102. Seront E, Schmitz S, Papier M, van Maanen A, Henry S, Lonchay C, Rottey

S, van Caloen G, Machiels JP. Phase 1 Study Evaluating the Association of

the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in

Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the

Head and Neck. Front Oncol. 2019;9:155.

Publications in national journals

1. Rottey S. Doelgerichte kankertherapieën. Tijdschrift Voor Geneeskunde.

2008;64(21):1087-1090.

2. De Corte W, Rottey S, Depuydt P, Nollet J, Phillipé J, Benoit D. Trombotische

microangiopathie als eerste teken van gemetastaseerd borstcarcinoom.

Tijdschrift Voor Geneeskunde. 2009;65(1):34-37.

3. Rottey S, Van Bortel L, Van Belle S. Complicaties van oncologische

therapie thuis opvangen. Tijdschrift Voor Geneeskunde. 2009;65(4):116-

119.

4. Lapeire L, Debruyne J, Rottey S. Mitoxantrone chemotherapie voor de

behandeling van Multiple Sclerose. Tijdschrift Voor Geneeskunde.

2009;65(20):967-970.

5. Geboes K, Rottey S, Laurent S, Vandenbroucke J, Peeters M. Doe-het-zelf

Chemotherapieadvies’: gevaarlijke ontwikkelingen via het internet.

Tijdschrift Voor Geneeskunde. 2011; 67(6):261-266.

6. Kruse V, Lumen N, D’Hondt F, Rottey S. An update on the systemic

treatment of renal cell cancer. Belg J Med Oncol 2012;6(1):13-22.

7. Decaestecker K, De Meerleer G, Rottey S, Lumen N, Fonteyne V,

Oosterlinck W. Blaasconserverende behandelingen voor invasieve

blaaskanker: een te weinig gebruikte mogelijkheid. Tijdschrift Voor

Geneeskunde 2012;68(6):290-294.

8. Lapeire L, Deron P, Duprez F, Rottey S. De plaats van cetuximab in de

behandeling van hoofd- en halstumoren. Tijdschrift Voor Geneeskunde

2012;68(17):807-815.

9. Van Praet C, De Maeseneer D, Lumen N, Rottey S. Attacking the

androgen receptor pathway in prostate cancer. Belg J Med Oncol

2013;7(4):111-118.

10. Vermassen T, Rottey S. Highlights in genitourinary cancer ESMO. Belg J Med

Oncol. 2014;8(4):143-146.

11. Vermassen T, Kerst JM, Tombal B, Rottey S. The first Belgian multidisciplinary

meeting on urological cancers. Belg J Med Oncol 2014;8(5):224-227.


12. El Ali Z, Van Brummelen D, Wolter P, Rottey S, Altintas S, Schallier D,

Debruyne P, Gennigens C, Van Aelst F, Sideris S, Gil T, Sirtaine N, D’Hondt

L, Luyten D, Focan C, Matus G, Rasschaert M, Pelgrims G. Management

and systemic treatment of clear cell mRCC: BSMO expert panel

recommendations. Belg J Med Oncol 2015;9(1):16-24.

13. Vermassen T, De Visschere P, Villeirs G, Schrijvers D, Rottey S. Second

Belgian multidisciplinary meeting on urological cancers held in Brussels –

March 28th, 2015. Belg J Med Oncol 2015;9(3):113-116.

14. Vermassen T, Rottey S. Highlights from ASCO 2015. Highlights in

genitourinary cancers. Belg J Med Oncol 2015;9(4):158-163.

15. Vermassen T, Rottey S. Highlights in genitourinary cancers. Belg J Med

Oncol 2015;9(6):244-249.

16. Rottey S, Van Bortel L, Christiaens T. Farmacotherapeutische actualiteit.

Tijdschrift Voor Geneeskunde 2015;71(17):1090-1094.

17. Delafontaine B, Van Lancker G, Van Bortel L, Rottey S. Virussen in de

behandeling van kanker: oncolytische virotherapie. Tijdschrift Voor

Geneeskunde. 2016;72(1):29-35.

18. Vermassen T, Rottey S. Highlights from ASCO 2016. Belg J Med Oncol.

2016;10(5):162-169.

19. Vermassen T, de Wit R, van Velthoven R, Albisinni S, Martinez Chanza N,

Aoun F, Seront E, Rottey S. 3rd Belgian Multidisciplinary Meeting on

Urological Cancers. Belg J Med Oncol. 2016;10(6):232-235.

20. Vermassen T, De Meulenaere A, Van de Walle M, Rottey S. Therapeutic

approaches in clear cell and non-clear cell renal cell carcinoma. Belg J

Med Oncol. 2016;10(7):256-262.

21. Vermassen T, Rottey S. ESMO 2016 – Highlights in genitourinary cancers.

Belg J Med Oncol. 2016;10(8):295-300.

22. Vermassen T, Rottey S, Van Bortel L, Christaens T. Framacotherapeutische

actualiteit. Tijdschrift Voor Geneeskunde. 2016;72(20):1154-1159.

23. Vermassen T, Rottey S. ASCO 2017 – Highlights in genitourinary cancers.

Belg J Med Oncol. 2017;11(4):155-60.


Belg J Med Oncol. 2017;11(7):326-333.

25. De Keukeleire S, Kruse V, Rottey S. Merkel cell carcinoma and immune

checkpoint inhibition: where do we stand now? Belg J Med Oncol.

2018;12;30-32 (BJMO Immuno-oncology Special).

26. Vermassen T, Rottey S. ASCO 2018 – Highlights in genitourinary cancers.

Belg J Med Oncol. 2018;12(4):189-195.


27. De Maeseneer D, Decaestecker K, Rottey S. Emerging concepts in

urothelial cancer. Belg J Med Oncol. 2018;12(5):212-217.

28. Standaert C, De Visschere PJ, Rottey S, Buelens S, Sundahl N, Villeirs GM.

MRI in prostate cancer diagnosis, surgical or radiation treatment, focal

therapy, active surveillance and follow-up. Belg J Med Oncol.

2018;12(7):313-318.


Belg J Med Oncol. 2018;12(8):373-379.

BOOKS AND BOOK CHAPTERS

1. Kosmidis P, Schrijvers D, André F, Rottey S (Editors). Handbook on Medical

Oncology Emergencies, ESMO. 2005

2. Rottey S, Van Belle S. Handbook on Medical Oncology Emergencies,

ESMO, Book Chapter Hypercalcemia.

3. Kosmidis P, Schrijvers D, André F, Rottey S (Editors). Handbook of

Oncological Emergencies, ESMO, Chinese edition. 2006

4. Rottey S. 99mTc-HYNIC Annexin-V for monitoring response to

chemotherapy : Methodology and feasibility studies.

5. Oncologie, Praktische huisartsgeneeskunde. S. Rottey Auteur van

hoofdstuk 14: Prostaatkanker en de rol van de huisarts. 2017

6. Vermassen T, Callewaert N, Rottey S, Delanghe Jr. Prostate Protein N-

Glycosylation Profiling by Means of DNA Sequencer-Assisted Fluorophore-

Assisted Carbohydrate Electrophoresis. Methods Mol Biol. 2019;1972:235-

250.

PATIENT INFO

Chemotherapie - Infobrochure voor kankerpatiënten en hun familie. VLK 2005

Wetenschappelijke lectuur : Sylvie Rottey en Jan Van Gaver

ABSTRACTS AND POSTERS

1. Everaert E, Rottey S, Cocquyt V, De Vos F, Dierickx RA, Sleghers G, Van de

Wiele C. Iodine labelled Tamoxifen uptake in primary and metastatic

breast cancer. Abstract presentation on BSMO, januari 2001.

2. Grosjean M, Rottey S, Benard J. IGR-BR-11, a new breast cancer cell line

model derived from a germinal BRCA1 mutation carrier. Abstract

American Association for Cancer Research 2002.

3. Rottey S, Sabourin JC, Grosjean M, Rixe O, Van Belle S, Benard J. Cultures

of primary breast cancer. Feasability of spheroid model. Abstract ESEC

(ESMO Summer Educational Conference Edinburgh) June 2003 + Poster


4. J. B. Vermorken, R. Mesia, M. E. Vega-Villegas, E. Remenar, R. Hitt, A.

Kawecki, S. Rottey, D. Zabolotnyy, J. Erfan, N. Amellal. Cetuximab in

combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the

first-line treatment of patients with recurrent and/or metastatic squamous

cell carcinoma of the head and neck (R&M SCCHN) (EXTREME). Journal

of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol

24, No. 18S (June 20 Supplement), 2006: 5537.

5. J. Vermorken, R. Mesia, V. Vega, E. Remenar, R. Hitt, A. Kawecki, S. Rottey,

N. Amellal, D. Cupissol, L. Licitra. Cetuximab extends survival of patients

with recurrent or metastatic SCCHN when added to first line platinum

based therapy - Results of a randomized phase III (Extreme) study. 2007

ASCO Annual Meeting, Oral Abstract Session, Head and Neck Cancer ,

Abstract No:6091.

6. T. E. Hutson, I. D. Davis, J. P. Machiels, P. L. de Souza, B. F. Hong, S. Rottey,

K. L. Baker, T. Crofts, L. Pandite, R. Figlin. Pazopanib (GW786034) is active

in metastatic renal cell carcinoma (RCC): Interim results of a phase II

randomized discontinuation trial (RDT). Journal of Clinical Oncology, 2007

ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20

Supplement), 2007: 5031.

7. I.Bambust , P.Pierre , E.Joossens , D.Schallier , F.Van Aelst , V.Renard ,

M.Clausse , R.Kalantari , R.Paulus , L.Duck , S.Luce , S.Rottey. A belgian

registry of interleukin-2 administration for treatment of metastatic renal

cell cancer. The Belgian Society for Fundamental and Clinical Physiology

and Pharmacology, november 2007, Oral presentation by S. Rottey

8. S. Rottey, H. Denys, H. Robays, L. Van Bortel, V. Cocquyt. Characteristics

and cardiac toxicity of thirty breast cancer patients treated with

trastuzumab in the adjuvant setting at the Ghent University Hospital

between June 2006 and July 2007: part of the trastuzumab convention.

De Nederlandse Vereniging voor Klinische Farmacologie & Biofarmacie,

april 2008, Utrecht : Oral presentation

9. S. Rottey, R. Hitt, A Kawecki, F. Peyrade, J.B. Vermorken

10. Cetuximab plus platinum-based chemotherapy vs platinum-based

chemotherapy alone in the first-line treatment of recurrent and/or

metastatic squamous cell carcinoma of the head and neck: a quality of

life analysis of the extreme trial. ICACT 2009 Poster

11. S Rottey, N Verbeke, L Vakaet, T Boterberg, W De Neve, K Bonte. Outcome

of T3 laryngeal cancer treated by primary surgery or primary

(chemo)radiation. ECCO 2009 Poster


12. V. Grunwald, J-P. Machiels, K. Miller, PI. Karakiewicz, SY. Rah, S. Rottey, M.

Staehler, C. Eichelberg, J. Ahn, S-H. Lee. An International Expanded

Access Program (EAP) of Afinitor® (everolimus) in patients with metastatic

renal cell carcinoma (mRCC) who fail, or become intolerant of a prior

vascular endothelial growth factor receptor (VEGFr) therapy. IKCS 2009

Abstract International Kidney Cancer Symposium

13. E. Seront, S. Rottey, B. Sautois, L. A. D'Hondt, J. R. Canon, J. Vandenbulcke,

N. Whenham, J. Goeminne, D. Verhoeven, J. H. Machiels. A single arm,

multicenter, phase II trial of everolimus as monotherapy in the palliative

treatment of patients with locally advanced or metastatic transitional cell

carcinoma after failure of platinum-based chemotherapy. J Clin Oncol 28,

2010 (suppl; abstr e15087)

14. J. B. Vermorken, J. H. Machiels, S. Rottey, H. C. Thurm, K. Pelling, A.

Lahogue. Phase Ib study evaluating the combination of BIBW 2992 with

two different standard chemotherapy regimens, cisplatin/paclitaxel (PT)

and cisplatin/5-FU (PF), in patients with advanced solid tumors. J Clin

Oncol 28, 2010 (suppl; abstr e13521).

15. E. Seront, B. Sautois, S. Rottey, L. A. D'Hondt, J. Canon, J. Vandenbulcke,

N. Whenham, J. C. Goeminne, O. Feron, J. H. Machiels Phase II trial of

everolimus monotherapy in the palliative treatment of patients with

metastatic transitional cell carcinoma (TCC) after failure of platinum-

based therapy: Activity and biomarkers. J Clin Oncol 29: 2011 (suppl; abstr

4622).

16. P. R. Debruyne, T. Boterberg, H. Pottel, L. Goethals, N. Van den Noortgate,

F. Duprez, W. De Neve, S. Rottey, K. Geldhof, K. Van Eygen, K. Kargar-

Samani, V. Ghekiere, F. Cornelis, S. G. Mohile, L. Pottel. Can the Vulnerable

Elders Survey-13 and/or the G8 adequately identify elderly patients with

head and neck cancer in need of a comprehensive geriatric assessment?

J Clin Oncol 29: 2011 (suppl; abstr e19670)

17. J. Vermorken, S. Rottey, E. Ehrnrooth, K. Pelling, A. Lahogue, J. Machiels. A

Phase Ib Open-label Study to Assess Continuous Oral Treatment With

Afatinib (BIBW 2992) in Combination With Two Chemotherapy Regimens –

Cisplatin Plus Paclitaxel, and Cisplatin Plus 5-fluorouracil in Patients, With

Advanced Solid Tumours. ESMO 2011, poster 1204.

18. V. Kruse, A. De Both, S. Van Belle, S. Rottey. Retrospective analysis of

metastatic renal cell cancer patients treated with sunitinib : does dose

matter? Abstract and oral presentation BSMO 2012


19. Bracarda, S., Rottey, S., Bahl, A., Eichelberg, C., Mellado, B., Mangel, L.,

Mardiak, J., Bouzaklas, I., Panneerselvam, A., Grünwald, V. International,

expanded-access programme of everolimus in patients with metastatic

renal cell carcinoma who progressed after prior vascular endothelial

growth factor receptor-tyrosine kinase inhibitor therapy: Sub-analysis of

European patients. Abstract EAU 2012

20. James Lloyd Wade, Shaker R. Dakhil, Ari David Baron, Sylvie Rottey,

Frederick E. Millard, Gedske Daugaard, Jean-Pascal H. Machiels, William

A. Conkright, Sunil Sharma, Patricia M.M.B. Soetekouw, Jeffrey Yachnin,

Lisa Sengeløv, Peter van Veldhuizen, Sanjiv S Agarwala, TX Quyen Nguyen,

Mustapha Chadjaa, Pierre Maison-Blanche. A QTc study of cabazitaxel in

patients with advanced solid tumors. J Clin Oncol 30, 2012 (suppl 5; abstr

257)

21. V. Kruse, A. De Both, S. Van Belle, S. Rottey. Retrospective analysis of

metastatic renal cell cancer patients treated with sunitinib : does dose

matter? Abstract oral presentation BSMO annual meeting 11/2/2012.

22. V. Kruse MD, A. De Both MD, N. Beck PharmD , L. Van Bortel MD PhD, S.

Van Belle MD PhD, S. Rottey MD PhD. Retrospective analysis of metastatic

renal cell cancer patients treated with sunitinib and the role of possible

interactions. Poster presentation NVKFB, 30/04/2012.

23. Pascal Wolter, Tine Hendrickx, Vincent Renard, Jeroen Mebis, Philip R.

Debruyne, Wim Wynendaele, Denis C. C. Schallier, Joanna Vermeij, Aldrik

Nielander, Jean-Pascal H. Machiels, Sylvie Rottey, Stephanie Delande,

Jean-Charles Goeminne, Patrick Schoffski, Sandra De Coster, Valerie

Lacour, Veerle Foulon Adherence to oral anticancer drugs (OAD) in

patients (pts) with metastatic renal cancer (mRCC): First results of the

prospective observational multicenter IPSOC study (Investigating Patient

Satisfaction with Oral Anti-cancer Treatment). 2012 ASCO Annual

Meeting; J Clin Oncol 30, 2012 (suppl; abstr 4622)

24. Jan Stoehlmacher-Williams, Cristian Villanueva, Paolo Foa, Sylvie Rottey,

Eric Winquist, Lisa F. Licitra, Irina Davidenko, Krzysztof A. Skladowski, Makoto

Tahara, Sandrine J. Faivre, Kelly S. Oliner, Zhiying Pan, Bruce A. Bach, Jan

Baptist Vermorken Safety and efficacy of panitumumab (pmab) in HPV-

positive (+) and HPV-negative (-) recurrent/metastatic squamous cell

carcinoma of the head and neck (R/M SCCHN): Analysis of the global

phase III SPECTRUM trial. 2012 ASCO Annual Meeting; J Clin Oncol 30, 2012

(suppl; abstr 5504^)

25. James Lloyd Wade, Shaker R. Dakhil, Ari David Baron, Sylvie Rottey,

Frederick E. Millard, Gedske Daugaard, Jean-Pascal H. Machiels, William

A. Conkright, Sunil Sharma, Patricia M.M.B. Soetekouw, Jeffrey Yachnin,


Lisa Sengeløv, Peter van Veldhuizen, Sanjiv S. Agarwala, TX Quyen

Nguyen, Mustapha Chadjaa, Pierre Maison-Blanche. A QTc study of

cabazitaxel in patients with advanced solid tumors. 2012 ASCO Annual

Meeting; J Clin Oncol 30, 2012 (suppl; abstr e15115)

26. Van Praet Charles, Lumen Nicolaas, Decaestecker Karel, Fonteyne

Valérie, De Meerleer Gert, De Maeseneer Daan, Van Belle Simon, Rottey

Sylvie. Abiraterone acetate for castration-resistant prostate cancer

following docetaxel: our initial experience. Global Congress On Prostate

Cancer, June 2012, Brussels

27. Awada, J.P. Delord, N. Houédé, C. Lebbe, T. Lesimple, J.H.M. Schellens, S.

Rottey, R. Kefford, N. Rejeb, E. Raymond. Safety and Recommended

Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib

(MSC1936369B/AS703026): Results of a Phase I Trial : poster presentation at

the 24th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer

Therapeutics’, 6-9 November 2012 Dublin, Ireland

28. N. Houédé, J.P. Delord, A. Awada, C. Lebbe, T. Lesimple, J.H.M. Schellens,

S. Rottey, R. Kefford, O. von Richter, E. Raymond. Pharmacokinetics and

Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib

(MSC1936369B/AS703026), in Patients with Advanced Solid Tumors. poster

presentation at the 24th EORTC-NCI-AACR Symposium on ‘Molecular

Targets and Cancer Therapeutics’, 6-9 November 2012 Dublin, Ireland

29. J.P. Delord, N. Houédé, A. Awada, C. Lebbe, T. Lesimple, J.H.M. Schellens,

S. Rottey, R. Kefford, N. Rejeb, E. Raymond. Pimasertib

(MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows

Clinical Activity in Melanoma. poster presentation at the 24th EORTC-NCI-

AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’, 6-9

November 2012 Dublin, Ireland

30. De Both A. , V. Kruse, E. De Coene, N. Clottens, A. Somers, S. van Belle, L.

van Bortel, S. Rottey. COMPLIANCE WITH SUNITINIB TREATMENT IN PATIENTS

WITH RENAL CELL CANCER. ESMO congress 2012, Vienna.

31. P.R. Debruyne, M. Lycke, T. Boterberg, H. Pottel, L. Goethals, N. van den

Noortgate, F. Duprez, S. Rottey, K. Kargar-Samani, L. Pottel. SERIAL

COMPREHENSIVE GERIATRIC EVALUATION IN ELDERLY HEAD AND NECK

CANCER PATIENTS UNDERGOING RADIOTHERAPY. Poster presentation at

ESMO congress 2012 Vienna.

32. Van Praet Charles, Libbrecht Louis, Rottey Sylvie, Praet Marleen, Van Belle

Simon, Lumen Nicolaas. Androgen receptor gene amplification in primary

prostate cancer patients. Poster op European Section on Urological

Research (ESUR) 10/2012


33. Prostate specific antigen glycosylation profile may serve as a diagnostic

biomarker for prostate cancer. Vermassen, T., Lumen, N., Van Praet, C.,

Vanderschaeghe, D., Callewaert, N., Hoebeke, P., Van Belle, S.,

Delanghe, J., Rottey, S. Abstract. Belg J Med Oncol 2013;7(2):63-67.

Accepted for oral presentation at 15th annual meeting Belgian Society for

Medical Oncology (BSMO), Brussels, 02/03/2013

34. Prostate specific antigen glycosylation profile may serve as a diagnostic

biomarker for prostate cancer. Vermassen, T., Van Praet, C., Lumen, N.,

Vanderschaeghe, D., Callewaert, N., Hoebeke, P., Van Belle, S.,

Delanghe, J., Rottey, S. Abstract 22. PROSCA Abstractbook 2013; p20.

Accepted for poster presentation at 2nd Edition of the Global Congress

on Prostate Cancer (PROSCA), Marseille, 12-14/06/2013.

35. Prostate proteins glycosylation profile and its potential as a diagnostic

biomarker for prostate cancer. Vermassen, T., Lumen, N., Van Praet, C.,

Vanderschaeghe, D., Callewaert, N., Hoebeke, P., Van Belle, S., Rottey, S.,

Delanghe, J. Abstract A-14. Clin Chem 2013; 59(10)S:A5. Accepted for oral

presentation at Annual Meeting American Association for Clinical

Chemistry (AACC), Houston, 31/07/2013

36. Prostate proteins glycosylation profile as a potential diagnostic biomarker

for prostate cancer. Vermassen, T., Van Praet, C., Vanderschaeghe, D.,

Lumen, N., Callewaert, N., Hoebeke, P., Van Belle, S., Rottey, S. , Delanghe,

J. Abstract 23. Oncopoint II Abstractbook 2014; p32. Accepted for oral

bullet presentation at OncoPoint II Ghent University, Ghent, 06/02/2014

37. Platinum-based chemotherapy (CT) plus cetuximab in recurrent or

metastatic squamous cell carcinoma of the head and neck cancer (R/M-

SCCHN): 5-year follow-up data for the extreme trial. Jan Baptist

Vermorken, Eva Remenar, Ricardo Hitt, Andrzej Kawecki, Sylvie Rottey,

Luise Knierim, Jeltje Schulten, Ricard Mesia J Clin Oncol 32:5s, 2014 (suppl;

abstr 6021)

38. A phase I, first-in-human study of ARGX-110, a monoclonal antibody

targeting CD70, a receptor involved in immune escape and tumor growth

in patients with solid and hematologic malignancies) Ahmad Awada,

Christian D. Rolfo, Sylvie Rottey, Laure Ysebrant de Lendonck, Wilfried A.

Schroyens, Fritz Offner, Karen Silence, Torsten Dreier, Mahan Moshir, Hans

de Haard, Marc Peeters, Dominique Bron, Alain Thibault, Philippe G.

Aftimos. J Clin Oncol 32:5s, 2014 (suppl; abstr 3023)

39. A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic

Ad11/Ad3 chimeric group B adenovirus, administered intravenously in

patients with metastatic epithelial tumors. Emiliano Calvo, Marta Gil-

Martin, Jean-Pascal H. Machiels, Sylvie Rottey, Antonio Cubillo, Ramon


Salazar, Feby Ingriani Mardjuadi, Karen Paula Geboes, Christopher Ellis,

John William Beadle, Christine Blanc. J Clin Oncol 32:5s, 2014 (suppl; abstr

3103)

40. Prostate proteins glycosylation profile as a potential diagnostic biomarker

for prostate cancer. Vermassen, T., Van Praet, C., Vanderschaeghe, D.,

Lumen, N., Callewaert, N., Hoebeke, P., Van Belle, S., Rottey, S. , Delanghe,

J. Wetenschapsdag Ghent University, Ghent, 13/03/2014. Accepted for

oral bullet presentation at Wetenschapsdag Ghent University, Ghent,

13/03/2014

41. Possible use of urinary prostate proteins glycosylation profile as a

diagnostic biomarker for prostate cancer.Vermassen, T., Lumen, N., Van

Praet, C., Vanderschaeghe, D., Callewaert, N., Hoebeke, P., Van Belle, S.,

Delanghe, J., Rottey, S. Abstract 236P. Ann Oncol 2014; 25(4)S:iv79.

Accepted for poster presentation at 39th annual congress European

Society for Medical Oncology (ESMO), Madrid, 26-30/09/2014.

42. Prostate cancer diagnosis through prostate proteins glycosylation.

Vermassen, T., Van Praet, C., Lumen, N., Decaestecker, K.,

Vanderschaeghe, D., Callewaert, N., Villeirs, G., Hoebeke, P., Van Belle, S.,

Delanghe, J., Rottey, S. Abstract 35. Oncopoint III Abstractbook 2015.

Accepted for oral bullet presentation at OncoPoint III Ghent University,

Ghent, 11/02/2015

43. Evaluation of abiraterone acetate post-docetaxel in the Belgian

compassionate use program. Sylvie Rottey, Charles Van Praet, Fransien

Van Hende, Gino Pelgrims, Wim Demey, Filip Van Aelst, Wim Wynendaele,

Thierry Gil, Peter Schatteman, Bertrand Filleul, Denis C. C. Schallier, Jean-

Pascal H. Machiels, Dirk L. Schrijvers, Els Grieta Everaert, Lionel A. D'Hondt,

Patrick Werbrouck, Joanna Vermeij, Jeroen Mebis, Marylene Clausse,

Nicolaas Lumen. J Clin Oncol 33, 2015 (suppl; abstr e16057)

44. Randomized phase II study of cabazitaxel versus methotrexate in patients

with recurrent or metastatic squamous cell carcinoma of the head and

neck (SCCHN) previously treated with platinum-based therapy. Sylvie

Rottey, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul,

Emmanuel Seront, Stefanie Henry, Lionel A. D'Hondt, Christophe Lonchay,

Stephane Holbrechts, Petra Boegner, Dany J. Brohee, Didier Dequanter,

Ingrid Louviaux, Brieuc Sautois, Nicolas Whenham, Guy J. Berchem, Brigitte

Vanderschueren, Christel Fontaine, Sandra Schmitz, Jean-Pascal H.

Machiels. J Clin Oncol 33, 2015 (suppl; abstr 6051)

45. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian

target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally

advanced or metastatic transitional cell carcinoma (TCC). Emmanuel

Seront, Sylvie Rottey, Bertrand Filleul, Phillipe Glorieux, Jean Charles.


Goeminne, Jean-Marie Vandenbulcke, Brieuc Sautois, Petra Boegner,

Vincent Verschaeve, Aline Gillain, Aline Van Maanen, Jean-Pascal H.

Machiels. J Clin Oncol 33, 2015 (suppl; abstr e15535).

46. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib

tablet formulation in patients with advanced solid tumours: Phase I open-

label studies. Elizabeth R. Plummer, Henk M.W. Verheul, Sylvie Rottey, Karin

Leunen, Guy Heinrich Maria Jerusalem, Christian D. Rolfo, Dorte L. Nielsen,

L Rhoda Molife, Rebecca Kristeleit, Judith de Vos-Geelen, Morten Mau-

Sørensen, Patricia M.M.B. Soetekouw, Carla van Herpen, Helen Swaisland,

Anitra Fielding, Karen So, Wendy Bannister, Luc Dirix. J Clin Oncol 33, 2015

(suppl; abstr 2565).

47. A. De Meulenaere, T. Vermassen, S. Aspeslagh, P. Deron, F. Duprez, K.

Silence, J. Jacobs, K. Zwaenepoel, P. Pauwels, S. Rottey, L. Ferdinande.

Immunohistochemical analysis of CD70 expression in 95 cases of

squamous cell carcinoma of the head and neck: Correlation with

clinicopathological variables and identification of a novel therapeutic

target. ECCO 2015, abstract 2880.

48. Vermassen, T., Poelaert, F., Lumen, N., Geboes, K., Delanghe, J., Rottey, S.

Assessment of renal toxicity in oncology patients treated with targeted

agents. Abstract. Belg J Med Oncol 2016. Poster presented at the Belgian

Society for Medical Oncology annual meeting, Brussels 27/02/2016.

49. De Meulenaere, A., Vermassen, T., Deron, F., Ferdinande, L., Rottey, S. A

pilot, phase Ib feasibility study of ARGX-110 in patients with

nasopharyngeal carcinoma (NPC). Abstract. Belg J Med Oncol 2016.

Poster presented at the Belgian Society for Medical Oncology annual

meeting, Brussels 27/02/2016.

50. Vermassen, T., Lumen, N., Delanghe, J., Rottey, S. Impact of haptoglobine

polymorphism on survival of renal cell carcinoma patients. Abstract 906P.

Ann Oncol 2017;28(S5):v295-v329. Poster presented at the European

Society for Medical Oncology annual meeting, Madrid 10/09/2017.

51. De Meulenaere, A., Vermassen, T., Rottey, S., Ferdinande, L. Phenotyping

of the immune infiltrate in oropharyngeal squamous cell carcinoma: focus

on materials and methods. Abstract 1063P. Ann Oncol 2017;28(S5):v372-

v394. Poster presented at the European Society for Medical Oncology

annual meeting, Madrid 10/09/2017.

52. Vermassen, T., Lumen, N., Delanghe, J., Rottey, S. Early biomarkers for TKI-

induced renal damage in mRCC patients. Abstract presented at the 6th

Belgian Multidisciplinary Meeting on Urological Cancers, Brussels

30/03/2019.


EXTRA-CURRICULAR ACTIVITIES AND MEMBERSHIPS

ESMO fellowship award 2001-2002 ESMO

Fellowship October 2001 – tember 2002

o Gustave Roussy institute (Service de Génétique, J. Benard, Villejuif,

Paris - research)

o Descartes University (Paris V) (Department Medical Oncology, D.

Khayat, Hôpital pitié Salpétrière, Paris – clinical trials)

Member of steering committee of Young Medical Oncologists of ESMO

(2000-2004)

Full Member of BSMO (Belgian Society of Medical Oncology)

Full member of ESMO (European Society of Medical Oncology)

Full member of ASCO (American Society of Medical Oncology)

Member of the Flemish Head and Neck Oncology Cooperative Group

Full Member of NVKFB (Nederlandse Vereniging voor Klinische

Farmacologie en Biofarmacie)

Full Member of BAPU (Belgian Association of Phase I Units)

Board Member of BAPU (since 25/06/2010)

Member of the multidisciplinary working group of uro-oncology at the

Ghent University Hospital

Member of the multidisciplinary working group of Head and Neck cancer

at the Ghent University Hospital

Member of committee of implantable ports of the Ghent University

Hospital , now IV team

Coordinating physician of the phase I oncology working group of the

Ghent University Hospital (from 2009)

Member of the FTC (Faramcotherapiecel) of the Ghent University Hospital

(start 2007)

Member of the MFC (Medisch Farmaceutisch Comite) of the Ghent

University Hospital (start 2009) – specialst in oncology

Member of the EORTC Head and Neck cancer working group

Member of the EORTC GU cancer working group

Member of the International Editorial Board of the journal ENHANCER 2006 -

2008

Member of the advisory board magazine VLK : Leven

Member of the editorial board ONCO from 2008


Member of the steering group organising postgraduate of internal

medicine of the University of Ghent

Reviewer of the journal

o Nephrology Dialysis Transplantation

o Acta Clinica Belgica

o Belgian Journal of Medical Oncology

o Oral Oncology

o European Journal of Nuclear Medicine and Molecular Imaging

o Advances in Urology

o Journal of Cancer Research and Clinical Oncology

o Onkologie

o Journal for Cancer research and Therapeutics

Coordinator LOK O-Vlaanderen (since 2008)

Member of Expert Meeting of the College of Oncology for the KCE Project

Testicular Cancer

Member ‘permanente werkgroep farmaca in de oncologie’ RIZIV

Member oncology care program / steering committee Ghent University

Hospital

Member of PONt (Psychosociaal Oncologisch team) from the oncology

care program Ghent University Hospital (start 10/2011).

Guest Editor ‘CME Series of Oncology for the Internist’ for Acta Clinica

Belgica, 2010 - 2011

Expert oncology for the bcfi – Belgisch Centrum voor Farmaceutische

Informatie

Member of numerous advisory boards on a national and international

level

Advisory Board Member for Framingham on Head and Neck cancer

(since 11/2011)

Co-editor of 7th edition (2011) of ‘Verpleegkundig oncologisch

compendium’

Experience in clinical trials phase I-III

Member of the BSMO prostate task force – president

Member of the BSMO renal cell cancer task force

Membre consultatif de la Fondation Registre du Cancer

National representative ESMO for Belgium (2013-2016)

Board member of the BSMO (start 2013)


GCP certificate renewal October 2013 – update on a yearly basis

Verantwoordelijke arts voorschrijverswerkgroep MFC UZGent Anti-emetica

en bifosfonaten (From 2013).

Rijksinstituut voor ziekte- en invaliditeitsverzekering. – Paritair comité voor

medische oncologie : werkend lid sinds juli 2013

2013 : IWT funding : ARGX-110 Adaptive Phase I Clinical Trial & Companion

Diagnostic Kit Development

2013 : Vlerick Business School, management voor de

ziekenhuisprofessional : Module people (2 days)

Module finance (2 days)

Chairman Expert Meeting of the College of Oncology for the KCE Project

renal cancer 2014-2015

Member of the KCE guideline development group : the Belgian clinical

practice guideline for the oncogenetic testing for 'BHD Syndrome, FAMMM

Syndrome, Neurofibromatosis 1&2' (2014)

Expert in the KCE project “Good Clinical Practice Guideline for Bladder

Cancer” Belgium 2014-2015

Board Member of the Flemish working group on Head and Neck cancers

(VWHHT) – since 6/2015

Vice president of MFC of the hospital (10/2015)

Vice president of BAPU (end of 2015)

Member of the editorial board of BJMO Belgian Journal of Medical

Oncology (1/2016)

PI of numerous phase I trials (Healthy Volunteers and Oncology patients)

in the Drug Research Unit Ghent

Member of CRIG (Cancer Research Institute Ghent) – CRIG group leader

(from 2016)

President of BMUC (Belgian Multidisciplinary Meeting on Urological

Cancers) since 2015

2017 : following course MDP – Management Development Program –

Ghent University Hospital – Ghent

Erkend opleider Klinische Farmacologie voor de NVKFB (de

NederlandseVereniging van Klinische Farmacologie en Biofarmacie)

since 2016

President of the scientific committee of the Pfizer Oncology Award since

2016


Member of the steering group on integrated care in CRPC setting

Jury member for the Galenus Prize for Pharmacology from 2020 onward

Expert oncologie Folia Pharmacotherapeutica

Member of the EHNS-European Head & Neck Society

President BAPU (March 2019)

Vice President BSMO (Feb 2019)

President FTC and MFC of UZGent

Replacing member CTG RIZIV

Member of the working group RIZIV : permanente werkgroep ONCO

Member of EUFEMED (European Federation for Exploratory Medicines

Development)

LANGUAGES

Dutch : fluent

English : fluent

French : fluent

German : basic knowledge

SOFTWARE

Practical knowledge of MS Office

LEISURE

Diploma oral presentation

Classical music (diploma violin)

Travelling

My Family

----------------------------------------------------------------------------------------------------------------------------------------

gert de schoenmakere · curriculum vitae sylvie rottey 1 sylvie rottey molenstraat 45 9890 gavere...

Documents